IXC — Invex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- AU$6.84m
- AU$1.03m
- AU$1.70m
- 78
- 61
- 64
- 75
Annual cashflow statement for Invex Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.166 | 0.159 | 0.262 | 1.26 | 1.7 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.6 | -1.68 | -3.38 | -6.87 | -2.44 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | 0 | — | — | — | — |
| Financing Cash Flow Items | -0.517 | -0.554 | 0 | 0 | -14 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 15.7 | 8.09 | 0 | 0 | -14 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.1 | 6.42 | -3.38 | -6.87 | -16.4 |